Nanovibronix (NASDAQ:FEED – Get Free Report) and Pulse Biosciences (NASDAQ:PLSE – Get Free Report) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, dividends, analyst recommendations, valuation, risk and profitability.
Institutional & Insider Ownership
16.4% of Nanovibronix shares are held by institutional investors. Comparatively, 77.0% of Pulse Biosciences shares are held by institutional investors. 12.2% of Nanovibronix shares are held by company insiders. Comparatively, 74.0% of Pulse Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Profitability
This table compares Nanovibronix and Pulse Biosciences’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Nanovibronix | -1,093.61% | -60.73% | -48.48% |
| Pulse Biosciences | -6,755.78% | -94.42% | -79.96% |
Volatility and Risk
Analyst Recommendations
This is a breakdown of current recommendations for Nanovibronix and Pulse Biosciences, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Nanovibronix | 1 | 0 | 0 | 0 | 1.00 |
| Pulse Biosciences | 1 | 0 | 5 | 1 | 2.86 |
Pulse Biosciences has a consensus price target of $50.20, suggesting a potential downside of 1.36%. Given Pulse Biosciences’ stronger consensus rating and higher probable upside, analysts plainly believe Pulse Biosciences is more favorable than Nanovibronix.
Earnings & Valuation
This table compares Nanovibronix and Pulse Biosciences”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Nanovibronix | $1.93 million | 0.18 | -$18.18 million | ($117.28) | -0.00 |
| Pulse Biosciences | $350,000.00 | 10,294.32 | -$72.78 million | ($1.18) | -43.13 |
Nanovibronix has higher revenue and earnings than Pulse Biosciences. Pulse Biosciences is trading at a lower price-to-earnings ratio than Nanovibronix, indicating that it is currently the more affordable of the two stocks.
Summary
Pulse Biosciences beats Nanovibronix on 9 of the 15 factors compared between the two stocks.
About Nanovibronix
NanoVibronix Inc. is a medical device company that is focused on creating medical products utilizing its proprietary low-intensity, surface acoustic wave technology. … NanoVibronix’ catheter-based products include the UroShield™ and NG-Shield™ devices that are both CE mark certified.
About Pulse Biosciences
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.
Receive News & Ratings for Nanovibronix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nanovibronix and related companies with MarketBeat.com's FREE daily email newsletter.
